Fortress Biotech, Inc.

Contributing Author

Recent Articles by Fortress Biotech, Inc.

Jan-13	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States FBIO -7.14% GlobeNewswire
Dec-15	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission FBIO +13.31% GlobeNewswire
Nov-14	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights FBIO +5.22% GlobeNewswire
Oct-21	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout FBIO GlobeNewswire
Oct-01	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing FBIO -30.72% GlobeNewswire
Oct-01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 FBIO -30.72% GlobeNewswire
Sep-02	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference FBIO +15.50% GlobeNewswire
Aug-14	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights FBIO +8.16% FBIO GlobeNewswire
May-30	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics FBIO GlobeNewswire
May-15	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights FBIO +7.23% GlobeNewswire
May-07	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference FBIO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.